Paul A Friedman
CIK 1236927 · Chief Executive Officer · last filed 2026-06-10
Paul A Friedman is a Chief Executive Officer who has filed 127 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for MDGL, was dated Sep 28, 2026. Across all open-market trades the lifetime net is −$322.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $411.6M across reported positions. 50 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 500,098 | $3.70 | $1.85M | $0 | 7 | 2026-06-10 |
| MDGL | Director | 865,744 | $437.74 | $378.97M | -$146.42M | 24 | 2026-01-13 |
| INCY | Director | 271,813 | $113.31 | $30.80M | -$175.53M | 41 | 2020-05-28 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 1,882 | — | — | $0 | 6 | 2017-04-05 |
| VSTM | Director | 250 | $10.00 | $2.5K | $24.9K | 3 | 2016-06-16 |
| MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Director | 5,681 | — | — | $0 | 3 | 2015-07-06 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 5,000 | — | — | -$1.00M | 23 | 2015-01-30 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | — | — | — | $0 | 1 | 2013-05-20 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | — | — | — | $0 | 1 | 2008-04-18 |
| BAUSCH & LOMB INC (BOL) Delisted | Director | 2,286 | — | — | $0 | 1 | 2007-09-25 |
Recent Filings
127 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-28 | MDGL | Notice (144) | −50,000 | -$25.83M | EDGAR |
| 2026-06-10 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2026-01-13 | MDGL | Mixed | — | -$149.9K | EDGAR |
| 2026-01-13 | MDGL | Mixed | — | -$12.42M | EDGAR |
| 2025-12-12 | MDGL | Mixed | — | -$13.30M | EDGAR |
| 2025-12-10 | MDGL | Notice (144) | −49,600 | -$27.47M | EDGAR |
| 2025-08-13 | MDGL | Notice (144) | −129,172 | -$46.37M | EDGAR |
| 2025-08-13 | MDGL | Mixed | — | -$46.60M | EDGAR |
| 2025-08-13 | MDGL | Mixed | — | -$16.19M | EDGAR |
| 2025-08-12 | MDGL | Notice (144) | −43,605 | -$15.24M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.